FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

WILLIAM SHARFMAN

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Co-author Network

Publications

TOP 3
Evan J Lipson; Drew M Pardoll; Alice Pons; WILLIAM SHARFMAN; Janis M Taube; Robert A Anders; Julie R Brahmer; Lieping Chen; Charles G Drake; Ira Wollner; Haiying Xu; Sheng Yao; Suzanne Topalian
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
Suzanne Topalian; JON WIGGINTON; Haiying Xu; Janis M Taube; Shruti Agrawal; Robert A Anders; Scott J Antonia; Michael B Atkins; Julie R Brahmer; Richard D Carvajal; Lieping Chen; Charles G Drake; Scott N Gettinger; Ashok Gupta; F Stephen Hodi; Leora Horn; Maria Jure-Kunkel; Georgia D Kollia; Alan J Korman; Philip D Leming; David F McDermott; Daniel McDonald; Tracee L McMiller; Drew M Pardoll; John D Powderly; WILLIAM SHARFMAN; David C Smith; Jeffrey A Sosman; David R Spigel; Mario Sznol
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Sharifeh Farasat; Siegrid S Yu; Victor A Neel; Kishwer S Nehal; Thomas Lardaro; Martin C Mihm; David R Byrd; Charles M Balch; Joseph A Califano; Alice Y Chuang; WILLIAM SHARFMAN; Jatin P Shah; Paul Nghiem; Clark C Otley; Anthony P Tufaro; Timothy M Johnson; Arthur J Sober; NANETTE LIEGEOIS
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of WILLIAM SHARFMAN (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Evan J Lipson; Drew M Pardoll; Alice Pons; WILLIAM SHARFMAN; Janis M Taube; Robert A Anders; Julie R Brahmer; Lieping Chen; Charles G Drake; Ira Wollner; Haiying Xu; Sheng Yao; Suzanne Topalian
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):462-8.
2012: Suzanne Topalian; JON WIGGINTON; Haiying Xu; Janis M Taube; Shruti Agrawal; Robert A Anders; Scott J Antonia; Michael B Atkins; Julie R Brahmer; Richard D Carvajal; Lieping Chen; Charles G Drake; Scott N Gettinger; Ashok Gupta; F Stephen Hodi; Leora Horn; Maria Jure-Kunkel; Georgia D Kollia; Alan J Korman; Philip D Leming; David F McDermott; Daniel McDonald; Tracee L McMiller; Drew M Pardoll; John D Powderly; WILLIAM SHARFMAN; David C Smith; Jeffrey A Sosman; David R Spigel; Mario Sznol
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
The New England journal of medicine 2012;366(26):2443-54.
2011: Sharifeh Farasat; Siegrid S Yu; Victor A Neel; Kishwer S Nehal; Thomas Lardaro; Martin C Mihm; David R Byrd; Charles M Balch; Joseph A Califano; Alice Y Chuang; WILLIAM SHARFMAN; Jatin P Shah; Paul Nghiem; Clark C Otley; Anthony P Tufaro; Timothy M Johnson; Arthur J Sober; NANETTE LIEGEOIS
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics.
Journal of the American Academy of Dermatology 2011;64(6):1051-9.
2010: Thomas Lardaro; Sofia M Shea; WILLIAM SHARFMAN; Nanette Liégeois; Arthur J Sober
Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging Manual.
Annals of surgical oncology 2010;17(8):1979-80.
2010: Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; WILLIAM SHARFMAN; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; MARTA GILSON; Changyu Wang; Mark Selby; Janis M Taube; Robert A Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne Topalian
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3167-75.
2010: Peter Hersey; Jeffrey Sosman; Steven O'Day; Jon Richards; Agop Bedikian; Rene Gonzalez; WILLIAM SHARFMAN; Robert Weber; Theodore Logan; Manuela Buzoianu; Luz D Hammershaimb; John M Kirkwood
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Cancer 2010;116(6):1526-34.
2005: Svetomir N Markovic; Susan M Geyer; Fitzroy W Dawkins; WILLIAM SHARFMAN; Mark Albertini; William J Maples; Paula M Fracasso; Tom R Fitch; Patricia M LoRusso; Alex A. Adjei; Charles Erlichman
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Cancer 2005;103(12):2584-9.
2005: WILLIAM SHARFMAN; Julie R Lange; Charles M Balch
Pediatric melanoma.
Pediatric blood & cancer 2005;44(5):431-2.
2001: John Janik; L L Miller; E L Korn; D Stevens; Brendan D Curti; J W Smith; Mario Sznol; K C Conlon; WILLIAM SHARFMAN; Walter J Urba; Barry L Gause; Dan Longo
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Blood 2001;97(7):1942-6.
1999: Dan Longo; PL Duffey; William Kopp; M P Heyes; W Gregory Alvord; WILLIAM SHARFMAN; P J Schmidt; David Rubinow; Donald Rosenstein
Conditioned immune response to interferon-gamma in humans.
Clinical immunology (Orlando, Fla.) 1999;90(2):173-81.
1998: Barry L Gause; WILLIAM SHARFMAN; John Janik; Brendan D Curti; R G Steis; W J Urba; J W Smith; W G Alvord; Dan Longo
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
Cancer investigation 1998;16(6):374-80.
1997: Arlene A Forastiere; Richard F Heitmiller; D J Lee; M Zahurak; RHODA ABRAMS; Lawrence Kleinberg; S Watkins; Charles J Yeo; Keith D Lillemoe; J V Sitzmann; WILLIAM SHARFMAN
Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus.
The cancer journal from Scientific American 1997;3(3):144-52.
1996: Robert G Fenton; R G Steis; K Madara; Arnold H Zea; Augusto C Ochoa; John Janik; J W Smith; Barry L Gause; WILLIAM SHARFMAN; W J Urba; M G Hanna; R L DeJager; M X Coyne; R D Crouch; P Gray; J Beveridge; Stephen Creekmore; J Holmlund; Brendan D Curti; Mario Sznol; Dan Longo
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(5):364-74.
1996: Barry L Gause; Mario Sznol; William Kopp; John Janik; J W Smith; R G Steis; W J Urba; WILLIAM SHARFMAN; Robert G Fenton; Stephen Creekmore; J Holmlund; K C Conlon; L A VanderMolen; Dan Longo
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2234-41.
1996: Brendan D Curti; Augusto C Ochoa; W J Urba; W Gregory Alvord; William Kopp; G Powers; C Hawk; Stephen Creekmore; Barry L Gause; John Janik; J T Holmlund; P Kremers; Robert G Fenton; L Miller; Mario Sznol; J W Smith; WILLIAM SHARFMAN; Dan Longo
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(4):296-308.
1996: Brendan D Curti; W J Urba; Dan Longo; John Janik; WILLIAM SHARFMAN; L L Miller; G Cizza; M Shimizu; J J Oppenheim; W Gregory Alvord; J W Smith
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(2):142-8.
1996: John Janik; L L Miller; Dan Longo; G C Powers; W J Urba; William Kopp; Barry L Gause; Brendan D Curti; Robert G Fenton; J J Oppenheim; K C Conlon; J T Holmlund; Mario Sznol; WILLIAM SHARFMAN; R G Steis; Stephen Creekmore; W Gregory Alvord; A E Beauchamp; J W Smith
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
Journal of the National Cancer Institute 1996;88(1):44-9.
1995: WILLIAM SHARFMAN; W Urba; J Smith; J Janik; B Curti; B Gause; J Holmlund; R Steis; A Beauchamp; D Longo
Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-cancer, renal-cell carcinoma and malignant-melanoma.
International journal of oncology 1995;6(3):579-83.
1993: John Janik; Mario Sznol; W J Urba; Robert Figlin; R M Bukowski; G Fyfe; W C Pierce; A Belldegrun; WILLIAM SHARFMAN; J W Smith
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors.
Cancer 1993;72(9):2656-9.
1993: J W Smith; Dan Longo; W Gregory Alvord; John Janik; WILLIAM SHARFMAN; Barry L Gause; Brendan D Curti; Stephen Creekmore; J T Holmlund; Robert G Fenton
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
The New England journal of medicine 1993;328(11):756-61.
1993: John Janik; William Kopp; J W Smith; Dan Longo; W Gregory Alvord; WILLIAM SHARFMAN; Robert G Fenton; Mario Sznol; R G Steis; Stephen Creekmore
Dose-related immunologic effects of levamisole in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):125-35.
1992: Richard K Burt; WILLIAM SHARFMAN; B I Karp; W H Wilson
Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse.
Cancer 1992;70(4):877-81.
1992: J W Smith; W J Urba; Brendan D Curti; L J Elwood; R G Steis; John Janik; WILLIAM SHARFMAN; L L Miller; Robert G Fenton; K C Conlon
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1141-52.
1992: Mario Sznol; R G Steis; J W Smith; John Janik; WILLIAM SHARFMAN; W J Urba; Robert G Fenton; Stephen Creekmore; J Beveridge; Dan Longo
Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.
The Online journal of current clinical trials 1992;Doc No 9():[3841 words; 32 paragraphs].
1992: Mario Sznol; jeffrey clark; J W Smith; R G Steis; W J Urba; L V Rubinstein; L A VanderMolen; John Janik; WILLIAM SHARFMAN; Robert G Fenton
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Journal of the National Cancer Institute 1992;84(12):929-37.
1992: W J Urba; C Ewel; W Kopp; J W Smith; R G Steis; J D Ashwell; Stephen Creekmore; J Rossio; Mario Sznol; WILLIAM SHARFMAN
Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.
Cancer research 1992;52(9):2394-401.
1991: Ronald M Bukowski; WILLIAM SHARFMAN; S Murthy; Patricia Rayman; Raymond Tubbs; J Alexander; G Thomas Budd; J S Sergi; L Bauer; V Gibson
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Cancer research 1991;51(16):4199-205.
1991: Ronald M Bukowski; J S Sergi; WILLIAM SHARFMAN; G Thomas Budd; S Murthy; Barbara P Barna; S V Medendorp; Belinda Yen-Lieberman; V Gibson; L Bauer
Phase I trial of natural human interferon beta in metastatic malignancy.
Cancer research 1991;51(3):836-40.
1990: WILLIAM SHARFMAN; T D Walsh
Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain?
Pain 1990;41(3):267-71.